Engineering Innovations Improve Process Column Chromatography

by Paul O’Neil and Ian Sellick
Volume 2, Issue 6 (November/December 2003)

Over the past decade there has been a steady increase in the number of biotherapeutics requiring high doses and long term administration. Most notable among these are monoclonal antibodies (MAbs) and fusion proteins comprised partially of antibody molecules. Column chromatography is a commonly applied purification method for downstream processing of biotherapeutics, and there is considerable pressure to process much greater volumes at a faster rate. For recombinant proteins and MAbs, a variety of chromatographic methods are employed, including affinity, ion exchange, hydrophobic interaction, and to a lesser extent, immobilized metal affinity and gel filtration. Improving process control for chromatography operations is essential for biopharmaceutical manufacturers to process larger volumes and overcome capacity shortfalls. As the past ten years have seen increasing volumes of MAb-based drugs, there have been significant innovations to address growing productivity requirements. Dominant among these has been high throughput media capable of isolating product at faster rates than previously achievable…

O’Neil P, Sellick I. Engineering Innovations Improve Process Column Chromatography. BioProcess J, 2003; 2(6): 57-60.